Cantex Pharmaceuticals, Inc.
Records under this name other than the patents Cantex Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 7 of 7 · Back to Cantex Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,734,804 | Treatment of myelosuppression Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,229,664 | Treatment of myelosuppression Lapsed on the fee record Ended Jan 25, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 25, 2026 | From the USPTO record |
| US 7,468,358 | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome Term ended Term ended Sep 7, 2025 · From the USPTO record | Term ended | Term ended Sep 7, 2025 | From the USPTO record |
| US 10,905,661 | Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms Lapsed on the fee record Ended Feb 2, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 2, 2025 | From the USPTO record |
| US 9,271,999 | Treatment of myelosuppression Lapsed on the fee record Ended Mar 1, 2024 · From the USPTO record | Lapsed on the fee record | Ended Mar 1, 2024 | From the USPTO record |
| US 6,489,311 | Method for the prevention of apoptosis Term ended Term ended May 2, 2020 · From the USPTO record | Term ended | Term ended May 2, 2020 | From the USPTO record |
| US 5,990,097 | Methods of treating asthma with o-desulfated heparin Term ended Term ended no later than Nov 23, 2019 · Low confidence | Term ended | Term ended no later than Nov 23, 2019 | Low confidence |